Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteFHD-286 is a BRG1/BRM ATPase inhibitor for the treatment of BAF-related disorders such as acute myeloid leukemia.
More Information Supplier PageFHD-286 is a BRG1/BRM ATPase inhibitor for the treatment of BAF-related disorders such as acute myeloid leukemia.
More Information Supplier PageFHT-1015 is a potent, small-molecule, allosteric inhibitor of SMARCA4/SMARCA2 ATPase with IC50 values ≤10 nM. FHT-1205 decreases PD1+TIM3+ cells and cytokine expression in vivo.
More Information Supplier PageFHT-1015 is a potent, small-molecule, allosteric inhibitor of SMARCA4/SMARCA2 ATPase with IC50 values ≤10 nM. FHT-1205 decreases PD1+TIM3+ cells and cytokine expression in vivo.
More Information Supplier PageFHT-1015 is a potent, small-molecule, allosteric inhibitor of SMARCA4/SMARCA2 ATPase with IC50 values ≤10 nM. FHT-1205 decreases PD1+TIM3+ cells and cytokine expression in vivo.
More Information Supplier PageFialuridine(FIAU, DRG-0098, NSC 678514) is a nucleoside analog with antiviral activity. It blocks DNAsynthesis in human cytomegalovirus and hepatitis B, as well as herpes simplex.
More Information Supplier PageFialuridine(FIAU, DRG-0098, NSC 678514) is a nucleoside analog with antiviral activity. It blocks DNAsynthesis in human cytomegalovirus and hepatitis B, as well as herpes simplex.
More Information Supplier PageFianlimab (Anti-LAG3 / CD223) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells. It has anti-tumour activity and can be used in treatment of advanced melanoma. MW :145.72 KD.
More Information Supplier PageFianlimab (Anti-LAG3 / CD223) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells. It has anti-tumour activity and can be used in treatment of advanced melanoma. MW :145.72 KD.
More Information Supplier PageFianlimab (Anti-LAG3 / CD223) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells. It has anti-tumour activity and can be used in treatment of advanced melanoma. MW :145.72 KD.
More Information Supplier PageFiclatuzumab (Anti-HGF / SF) is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). It inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion and can be used to treat head and neck squamous cell carcinoma (HNSCC). MW :150 KD.
More Information Supplier PageFiclatuzumab (Anti-HGF / SF) is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). It inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion and can be used to treat head and neck squamous cell carcinoma (HNSCC). MW :150 KD.
More Information Supplier PageFiclatuzumab (Anti-HGF / SF) is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). It inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion and can be used to treat head and neck squamous cell carcinoma (HNSCC). MW :150 KD.
More Information Supplier PageFicoll(R) 400 (sucrose-epichlorohydrin copolymer) is a macromolecular crowder that plays a pivotal role in promoting liquid-liquid phase separation (LLPS) of proteins. It is currently utilized in the isolation of serum and peripheral blood mononuclear cells (PBMC) from the whole blood of Parkinson’s disease (PD) patients.
More Information Supplier PageFicoll(R) 400 (sucrose-epichlorohydrin copolymer) is a macromolecular crowder that plays a pivotal role in promoting liquid-liquid phase separation (LLPS) of proteins. It is currently utilized in the isolation of serum and peripheral blood mononuclear cells (PBMC) from the whole blood of Parkinson’s disease (PD) patients.
More Information Supplier PageFicus Carica Extract is obtained from Ficus carica Linn. (Moraceae), which has been used in traditional medicine for a wide range of ailments related to digestive, endocrine, reproductive, and respiratory systems.
More Information Supplier PageFicus Hirta Vahl Extract is derived from Ficus hirta Vahl. (Wuzhimaotao), which possesses hepatoprotective, antibacterial, and anti-inflammatory bioactivities and improves memory function of AD mice.
More Information Supplier PageFICZ (6-Formylindolo[3,2-b]carbazole) is a potent agonist of aryl hydrocarbon receptor (AhR) that is efficiently metabolized by AHR-regulated cytochrome P4501 enzymes.
More Information Supplier PageFICZ (6-Formylindolo[3,2-b]carbazole) is a potent agonist of aryl hydrocarbon receptor (AhR) that is efficiently metabolized by AHR-regulated cytochrome P4501 enzymes.
More Information Supplier PageFICZ (6-Formylindolo[3,2-b]carbazole) is a potent agonist of aryl hydrocarbon receptor (AhR) that is efficiently metabolized by AHR-regulated cytochrome P4501 enzymes.
More Information Supplier PageFICZ (6-Formylindolo[3,2-b]carbazole) is a potent agonist of aryl hydrocarbon receptor (AhR) that is efficiently metabolized by AHR-regulated cytochrome P4501 enzymes.
More Information Supplier PageFIDAS-3 effectively competes against S-adenosylmethionine (SAM) for methionine sadenosyltransferase 2A (MAT2A) binding . FIDAS-3 has anticancer activities by inhibiting the expression of oncogenes. FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC50 of 4.9 μM for MAT2A.
More Information Supplier PageFidaxomicin is a narrow spectrum macrocyclic antibiotic that inhibits RNA polymerase sigma subunit.
More Information Supplier PageFidaxomicin is a narrow spectrum macrocyclic antibiotic that inhibits RNA polymerase sigma subunit.
More Information Supplier PageFigitumumab (Anti-IGF1R / CD221) is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. MW: 146.0 KD.
More Information Supplier PageFigitumumab (Anti-IGF1R / CD221) is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. MW: 146.0 KD.
More Information Supplier PageFigitumumab (Anti-IGF1R / CD221) is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. MW: 146.0 KD.
More Information Supplier PageFIIN-2 is an irreversible, pan-FGFR inhibitor with IC50 of 3.09 nM, 4.3 nM, 27 nM and 45.3 nM for FGFR1/2/3/4, respectively.
More Information Supplier PageFIIN-2 is an irreversible, pan-FGFR inhibitor with IC50 of 3.09 nM, 4.3 nM, 27 nM and 45.3 nM for FGFR1/2/3/4, respectively.
More Information Supplier PageFIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
More Information Supplier PageFilanesib (ARRY-520) hydrochloride is a kinesin spindle protein (KSP) inhibitor that blocks the separation of centrosomes and assembly of spindles in the early stage of cell mitosis, and cell proliferation.
More Information Supplier PageFilanesib (ARRY-520) hydrochloride is a kinesin spindle protein (KSP) inhibitor that blocks the separation of centrosomes and assembly of spindles in the early stage of cell mitosis, and cell proliferation.
More Information Supplier PageFilastatin, a long-lasting inhibitor of Candida albicans filamentation, inhibits adhesion by multiple pathogenic Candida species with an IC50 of ~3 μM in the GFP-based adhesion assay.
More Information Supplier PageFilgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.
More Information Supplier PageFilgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.
More Information Supplier PageFilgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.
More Information Supplier PageFilgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.
More Information Supplier PageFilgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.
More Information Supplier PageFimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure.
More Information Supplier PageCUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively. CUDC-907 induces cell cycle arrest and apoptosis in breast cancer cells. Phase 1.
More Information Supplier PageCUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively. CUDC-907 induces cell cycle arrest and apoptosis in breast cancer cells. Phase 1.
More Information Supplier PageFinasteride (MK-906) is a potent, reversible inhibitor of the rat type 1 5 alpha-reductase withKi of 10.2 nM, used in the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).
More Information Supplier PageFineleaf Schizonepeta Herb Extract is extracted from the leaves of Schizonepeta, which is used as a traditional medicine with antipyretic, anti-inflammatory, analgesic, and hemostatic effects.
More Information Supplier PageFinerenone (FIN, BAY 94-8862) is a highly selective and orally available nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
More Information Supplier PageFinerenone (FIN, BAY 94-8862) is a highly selective and orally available nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
More Information Supplier Page
